Improving the magnetic heating by disaggregating nanoparticles

Recently, potential applications of the magnetic heating for heterogeneous catalysis or organic synthesis have been reported. As these new applications are not limited by biocompatibility requirements, a wide range of possibilities for non-aqueous colloidal nanoparticles with enhanced magnetic properties is open. In this work, manganese and cobalt ferrite nanoparticles are synthesized by co-precipitation method with average particle size around 12 nm. The particles are either coated with tetramethylammonium hydroxide (TMAOH) and dispersed in water or with oleic acid (OA) and dispersed in hexane to produce aggregated or disaggregated nanoparticles, respectively. It is observed that the particle disaggregation improves significantly the heating efficiency from 12 to 96 W/g in the case of cobalt ferrite, and from 120 to 413 W/g for the manganese ferrite. The main responsible for this improvement is the reduction of hydrodynamic volume that allows a faster Brownian relaxation. This work also discusses the relevance of the size distribution

Experimental Electron Density Study of Tetrakis-mu-(acetylsalicylate)dicopper(II): a Polymeric Structure with Cu center dot center dot center dot Cu Short Contacts

International audienceThe electron density, its topological features, and the electrostatic potential of tetrakis-mu-(acetylsalicylate)dicopper(II), Cu[C9H7O4](2), have been derived from an accurate high-resolution diffraction experiment at 100 K. This complex exhibits a polymeric structure involving one acetyl oxygen atom as a bridge in the solid state. Only van der Waals interactions between the polymeric chains are observed. The copper cation is octahedrally coordinated with five oxygen atoms of the aspirinate ligands and one adjacent Cu with short Cu center dot center dot center dot Cu contact distances in the range of 2.6054(1) angstrom. The Cu-O bond lengths are equal to 1.96 angstrom except the apical one which is 2.2183(7) angstrom. The multipole refinements were carried out using the Hansen-Coppens model coded in the MOPRO computer program. Starling from the 3d(10)4s(1) copper electron configuration, the electron density analysis and Cu d-orbital populations reveal that the observed configuration is close to being [Ar]3d(9)4s(1). As expected from the ligand field theory, the most depopulated 3d-orbital is the d(x2-y2)(1.17 e) one with lobes pointing toward the carboxylic oxygen atoms. Conversely, the d(z2) is the most populated orbital for a z-axis directed along the Cu center dot center dot center dot Cu bond. The atomic charges were derived from a kappa-refinement and yielded a metal net charge of +1.20(3) e. Deficits of +0.72(6) and +0.59(7) e are obtained for the acetyl carbon atoms of the aspirinate ligands, those involved in the drug activity of aspirin. Comparisons are made to the results of our previous work on the zinc-aspirinate complex

Effect of Al content on the hardness and thermal stability study of AlTiN and AlTiBN coatings deposited by HiPIMS

The microstructure, mechanical properties and thermal stability of AlxTi1 xN and Al1Ti1-xBN coatings grown by reactive high-power impulse magnetron sputtering (HiPIMS) have been analyzed as a function of Al/(Al + Ti) ratio (x) between 0.5 and 0.8. The coatings were predominantly formed by a face-centered cubic Ti(Al)N crystalline phase, both with and without B, even for x ratios as high as 0.6, which is higher than the ratio typically encountered for AlxTi1 xN coatings deposited by reactive magnetron sputtering. B doping, in combination with the highly energetic deposition conditions offered by HiPIMS, results in the suppression of the columnar grain morphology typically encountered in AlxTi1 xN coatings. On the contrary, the AlxTi1 xBN coatings grown by HiPIMS present a dense nanocomposite type microstructure, formed by nanocrystalline Ti(Al) N domains and amorphous regions composed of Ti(Al)B2 and BN. As a result, high-Al content (x ≈ 0.6) AlxTi1 xBN coatings grown by HiPIMS offer higher hardness, elasticity and fracture toughness than AlxTi1 xN coatings. Moreover, the thermal stability and the hot hardness are substantially enhanced, delaying the onset of formation of the detrimental hexagonal AlN phase from 850 ◦C in the case of Al0.6Ti0.4N, to 1000 ◦C in the case of Al0.6Ti0.4BN.Peer reviewe

Skewness and kurtosis of mean transverse momentum fluctuations at the LHC energies

The first measurements of skewness and kurtosis of mean transverse momentum (〈pT〉) fluctuations are reported in Pb–Pb collisions at sNN = 5.02 TeV, Xe–Xe collisions at sNN = 5.44 TeV and pp collisions at s=5.02 TeV using the ALICE detector. The measurements are carried out as a function of system size 〈dNch/dη〉|η|<0.51/3, using charged particles with transverse momentum (pT) and pseudorapidity (η), in the range 0.2<pT<3.0 GeV/c and |η|<0.8, respectively. In Pb–Pb and Xe–Xe collisions, positive skewness is observed in the fluctuations of 〈pT〉 for all centralities, which is significantly larger than what would be expected in the scenario of independent particle emission. This positive skewness is considered a crucial consequence of the hydrodynamic evolution of the hot and dense nuclear matter created in heavy-ion collisions. Furthermore, similar observations of positive skewness for minimum bias pp collisions are also reported here. Kurtosis of 〈pT〉 fluctuations is found to be in good agreement with the kurtosis of Gaussian distribution, for most central Pb–Pb collisions. Hydrodynamic model calculations with MUSIC using Monte Carlo Glauber initial conditions are able to explain the measurements of both skewness and kurtosis qualitatively from semicentral to central collisions in Pb–Pb system. Color reconnection mechanism in PYTHIA8 model seems to play a pivotal role in capturing the qualitative behavior of the same measurements in pp collisions

System-size dependence of the hadronic rescattering effect at energies available at the CERN Large Hadron Collider

International audienceThe first measurements of K*(892)0 resonance production as a function of charged-particle multiplicity in Xe-Xe collisions at sNN=5.44 TeV and pp collisions ats=5.02 TeV using the ALICE detector are presented. The resonance is reconstructed at midrapidity (|y| &lt; 0.5) using the hadronic decay channel K*0 →K±π∓. Measurements of transverse-momentum integrated yield, mean transverse-momentum, nuclear modification factor of K*0, and yield ratios of resonance to stable hadron (K*0/K) are compared across different collision systems (pp, p-Pb, Xe-Xe, and Pb-Pb) at similar collision energies to investigate how the production of K*0 resonances depends on the size of the system formed in these collisions. The hadronic rescattering effect is found to be independent of the size of colliding systems and mainly driven by the produced charged-particle multiplicity, which is a proxy of the volume of produced matter at the chemical freeze-out. In addition, the production yields of K*0 in Xe-Xe collisions are utilized to constrain the dependence of the kinetic freeze-out temperature on the system size using the hadron resonance gas–partial chemical equilibrium model

International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module

•We report INICC device-associated module data of 50 countries from 2010-2015.•We collected prospective data from 861,284 patients in 703 ICUs for 3,506,562 days.•DA-HAI rates and bacterial resistance were higher in the INICC ICUs than in CDC-NHSN's.•Device utilization ratio in the INICC ICUs was similar to CDC-NHSN's. Background: We report the results of International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2010-December 2015 in 703 intensive care units (ICUs) in Latin America, Europe, Eastern Mediterranean, Southeast Asia, and Western Pacific. Methods: During the 6-year study period, using Centers for Disease Control and Prevention National Healthcare Safety Network (CDC-NHSN) definitions for device-associated health care-associated infection (DA-HAI), we collected prospective data from 861,284 patients hospitalized in INICC hospital ICUs for an aggregate of 3,506,562 days. Results: Although device use in INICC ICUs was similar to that reported from CDC-NHSN ICUs, DA-HAI rates were higher in the INICC ICUs: in the INICC medical-surgical ICUs, the pooled rate of central line-associated bloodstream infection, 4.1 per 1,000 central line-days, was nearly 5-fold higher than the 0.8 per 1,000 central line-days reported from comparable US ICUs, the overall rate of ventilator-associated pneumonia was also higher, 13.1 versus 0.9 per 1,000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 5.07 versus 1.7 per 1,000 catheter-days. From blood cultures samples, frequencies of resistance of Pseudomonas isolates to amikacin (29.87% vs 10%) and to imipenem (44.3% vs 26.1%), and of Klebsiella pneumoniae isolates to ceftazidime (73.2% vs 28.8%) and to imipenem (43.27% vs 12.8%) were also higher in the INICC ICUs compared with CDC-NHSN ICUs. Conclusions: Although DA-HAIs in INICC ICU patients continue to be higher than the rates reported in CDC-NSHN ICUs representing the developed world, we have observed a significant trend toward the reduction of DA-HAI rates in INICC ICUs as shown in each international report. It is INICC's main goal to continue facilitating education, training, and basic and cost-effective tools and resources, such as standardized forms and an online platform, to tackle this problem effectively and systematically

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)